What is the 13F Pro Quality Score for FENC?

13F Pro ranks FENNEC PHARMACEUTICALS INC. (FENC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FENC's current score at https://13fpro.ai/company/FENC (free sign-up required for the full ranking).

Where does 13F Pro source FENC data?

All FENNEC PHARMACEUTICALS INC. fundamentals and ownership data come directly from SEC EDGAR. FENNEC PHARMACEUTICALS INC. files with the SEC under CIK 1211583. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FENC in?

FENNEC PHARMACEUTICALS INC. (FENC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FENC research updated on 13F Pro?

FENC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FENNEC PHARMACEUTICALS INC.(FENC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1211583 FENC stock profile & AI dashboard →

13F Pro Quality Score

35.7/100

Rank #2,297 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.7/100

Profitability

33.8/100

Balance Sheet

22.3/100

Earnings Quality

30.1/100

Free Cash Flow

21.6/100

Institutional Flow

23.0/100

Revenue Scale

10.4/100

Dilution Risk

11.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FENC Scores 36/100

exact factor attribution · 2026-09-11

FENC's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.5 pts

78th pct

Earnings growth

+0.9 pts

68th pct

Institutional flow

-1.4 pts

23th pct

Shareholder dilution

-1.9 pts

11th pct

Earnings quality

-2.0 pts

30th pct

Profitability

-2.4 pts

34th pct

Capital efficiency

-2.8 pts

22th pct

Free cash flow

-4.3 pts

22th pct

Scale

-5.9 pts

10th pct

Latest change (2026-08-16): 27 → 38 · ↑ Revenue growth 65→96; ↑ Profit margin 19→43

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in FENC

Events flagged as statistical outliers against FENC's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-16
FENC quality score jumped 11 points (27→38) on a new filing
View source filing →

FENC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for FENNEC PHARMACEUTICALS INC. (FENC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FENC at 35.7/100 on a 32-signal composite quality model, placing it at rank #2,297 of 2,962 stocks — the bottom half of the AI-ranked universe. FENC scores in the top quartile across revenue growth (77.7). Areas of concern include revenue scale (10.4) and free cash flow (21.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), FENNEC PHARMACEUTICALS INC. reports quarterly revenue of $17.9M, net income of $2.0M. Top institutional holders of FENC by reported 13-F value include Rosalind Advisors, AIGH Capital Management, Solas Capital Management, based on the most recent SEC filings. FENC trades on the Nasdaq exchange and files with the SEC under CIK 1211583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FENC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FENNEC PHARMACEUTICALS INC. directly from SEC EDGAR. FENNEC PHARMACEUTICALS INC.'s 13F Pro composite quality score has ranged between 13 and 60 since 2025, currently 35.7 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about FENNEC PHARMACEUTICALS INC.

Quirks, history, and lore behind FENC — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap specialty pharmaceutical company · listed on Nasdaq · headquartered in New York.
2
The Numbers
Annual revenue in the low tens of millions — this is a commercial-stage biotech with a very focused, single-product pipeline rather than a sprawling drug portfolio.
3
The History
Founded in Canada and later redomiciled to the U.S., the company spent years pursuing FDA approval for a drug to protect pediatric cancer patients from a brutal chemotherapy side effect.
4
The Secret
Its lead drug targets ototoxicity — the hearing loss caused by cisplatin chemotherapy in children — a niche so overlooked that no approved treatment existed for decades.
5
The Lore
Its flagship product, sodium thiosulfate, is a compound known since the 19th century, yet the company figured out how to get it FDA-approved as a named drug for kids with cancer.
6
The Giveaway
The company's name evokes a small, clever North American canid — fitting for a tiny pharma firm that quietly won approval for PEDMARK, the first therapy to prevent hearing loss in pediatric cisplatin patients.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$17.9M

Net Income

Q2 2026

$2.0M

ROIC

Q2 2026

16.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-6.1% YoY

$44.6MFY 2025

FY22 $1.5MFY23 $21.3MFY24 $47.5MFY25 $44.6M

Net Income

-2134.2% YoY

$-9.7MFY 2025

FY22 $-23.7MFY23 $-16.0MFY24 $-436.0KFY25 $-9.7M

Operating Income

-344.6% YoY

$-6.3MFY 2025

FY22 $-22.6MFY23 $-12.8MFY24 $2.6MFY25 $-6.3M

EPS (Diluted)

-1600.0% YoY

$-0.34FY 2025

FY22 $-0.90FY23 $-0.60FY24 $-0.02FY25 $-0.34

Total Assets

+57.0% YoY

$70.6MFY 2025

FY22 $26.9MFY23 $26.9MFY24 $44.9MFY25 $70.6M

Total Debt

—FY 2025

FY22 $24.9MFY23 $30.9MFY24 $19.3MFY25 —

Op. Cash Flow

-146.2% YoY

$-12.5MFY 2025

FY22 $-18.1MFY23 $-17.1MFY24 $27.0MFY25 $-12.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$44.6M -6.1%	$47.5M +123.7%	$21.3M +1284.5%	$1.5M	—	$170.0K
Net Income	$-9.7M -2134.2%	$-436.0K +97.3%	$-16.0M +32.3%	$-23.7M -36.7%	$-17.3M +4.2%	$-18.1M
Operating Income	$-6.3M -344.6%	$2.6M +120.1%	$-12.8M +43.5%	$-22.6M -31.2%	$-17.2M +3.7%	$-17.9M
EPS (Diluted)	$-0.34 -1600.0%	$-0.02 +96.7%	$-0.60 +33.3%	$-0.90 -34.3%	$-0.67 +11.8%	$-0.76
Total Assets	$70.6M +57.0%	$44.9M +67.3%	$26.9M -0.3%	$26.9M +20.2%	$22.4M -28.7%	$31.4M
Total Debt	—	$19.3M -37.5%	$30.9M +24.2%	$24.9M +398.0%	$5.0M	—
Operating Cash Flow	$-12.5M -146.2%	$27.0M +257.4%	$-17.1M +5.1%	$-18.1M -27.0%	$-14.2M +8.8%	$-15.6M

Get alerted when FENC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FENNEC PHARMACEUTICALS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FENC

Rosalind Advisors, Inc.
$34.3M3,188,001 sh
AIGH Capital Management LLC
$26.7M2,486,038 sh
Solas Capital Management, LLC
$20.3M1,889,366 sh
BlackRock, Inc.
$18.6M1,727,069 sh
AWM Investment Company, Inc.
$12.5M1,160,296 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.0M839,306 sh
Prospect Capital Advisors, LLC
$5.4M497,800 sh
STATE STREET CORP
$4.6M426,004 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.3M402,566 sh
JANE STREET GROUP, LLC
$2.5M233,877 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$34.3M	3,188,001
AIGH Capital Management LLC	$26.7M	2,486,038
Solas Capital Management, LLC	$20.3M	1,889,366
BlackRock, Inc.	$18.6M	1,727,069
AWM Investment Company, Inc.	$12.5M	1,160,296
VANGUARD CAPITAL MANAGEMENT LLC	$9.0M	839,306
Prospect Capital Advisors, LLC	$5.4M	497,800
STATE STREET CORP	$4.6M	426,004
GEODE CAPITAL MANAGEMENT, LLC	$4.3M	402,566
JANE STREET GROUP, LLC	$2.5M	233,877

Companies Similar to FENC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BFRI

Biofrontera Inc.

AI score

Very similar · 2 shared holders

Rosalind Advisors, Inc.AIGH Capital Management LLC

MYO

MYOMO, INC.

AI score

Similar quality profile · 1 shared holders

Rosalind Advisors, Inc.

KIDS

ORTHOPEDIATRICS CORP

AI score

Similar quality profile · 3 shared holders

AIGH Capital Management LLC AWM Investment Company, Inc.CenterBook Partners LP

APYX

Apyx Medical Corp

AI score

Similar quality profile · 1 shared holders

AIGH Capital Management LLC

ABEO

ABEONA THERAPEUTICS INC.

AI score

Similar quality profile · 2 shared holders

AIGH Capital Management LLC AWM Investment Company, Inc.

BDSX

BIODESIX INC

AI score

Similar quality profile · 1 shared holders

AIGH Capital Management LLC

CERS

CERUS CORP

AI score

Similar quality profile · 1 shared holders

Round Rock Advisors, LLC

CYRX

Cryoport, Inc.

AI score

Similar quality profile · 2 shared holders

CenterBook Partners LP AWM Investment Company, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FENC on your watchlist

Track score changes the day FENNEC PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FENC a good stock to buy?

13F Pro's AI-powered analysis of FENNEC PHARMACEUTICALS INC. (FENC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FENC are available on the FENC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FENC is classified as a small company.

Which hedge funds own FENC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FENC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FENNEC PHARMACEUTICALS INC.'s investment landscape.